Avalo Therapeutics, Inc.

AVTX · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$35,129-$31,544-$41,658-$84,376
Dep. & Amort.$169$158$166$1,657
Deferred Tax$114$14$28$22
Stock-Based Comp.$5,852$3,477$0$8,172
Change in WC-$4,708-$9,240-$60$2,839
Other Non-Cash-$15,354$6,455$14,773$794
Operating Cash Flow-$49,056-$30,680-$26,751-$70,892
Investing Activities
PP&E Inv.$0-$158-$95-$113
Net Acquisitions$356$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$25$0$0
Investing Cash Flow$356-$133-$95-$113
Financing Activities
Debt Repay.$0-$21,244-$14,806$32,900
Stock Issued$115,625$46,219$107$71,929
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$60,224$67$0$1,933
Financing Cash Flow$175,849$25,042-$14,699$106,762
Forex Effect$0$0$96$0
Net Chg. in Cash$127,149-$5,771-$41,449$35,757
Supplemental Information
Beg. Cash$7,547$13,318$54,636$19,106
End Cash$134,696$7,547$13,187$54,863
Free Cash Flow-$49,056-$30,838-$26,846-$71,005
Avalo Therapeutics, Inc. (AVTX) Financial Statements & Key Stats | AlphaPilot